Clinical trials: A
Weight Change, Body
Healthy Homes/Healthy Families (HH/HF) Intervention in 2-1-1 Callers
This trial will evaluate a healthy eating and weight gain prevention intervention for delivery through calls to the 2-1-1 number.
- Trial name
- NCT04373434
- Testing
- Health Homes/Healthy Families (HH/HF) Intervention, Control
- Where
- United States
- Volunteers
- 512 people
- Sponsor
- Emory University
Adolescent Idiopathic Scoliosis
Application of Virtual Reality in Post-Operative Recovery of a Pediatric Scoliosis Patient Population
The purpose of this study is to assess the effect of virtual reality on subjective post-operative pain, total inpatient narcotic administration, and mobilization with physical therapy in pediatric patients who have undergone…
- Trial name
- NCT06101264
- Testing
- Control, Virtual Reality
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Connecticut Children's Medical Center
Atherosclerotic Lesion(s)
EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
The purpose of this study is to evaluate 9 month angiographic and intravascular ultrasound (IVUS) data for the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) in the treatment of subjects…
- Trial name
- EVOLVE II QCA (NCT01787799)
- Testing
- SYNERGY
- Where
- 13 sites in Australia, Japan and 2 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Healthy Adult Subjects
A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
To evaluate the pharmacokinetics of single and multiple doses of pegilodecakin in healthy participants.
- Trial name
- Willow 1 (NCT03267732)
- Testing
- Pegilodecakin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
This study evaluated bradycardiac events during first dose observation of fingolimod in MS patients.
- Trial name
- START (NCT01585298)
- Testing
- FTY720
- Where
- 258 sites in Germany
- Volunteers
- 6,998 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Musculoskeletal Complications
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy
RATIONALE: Duloxetine hydrochloride may lessen muscle, bone, and joint pain caused by hormone therapy. It is not yet known whether duloxetine hydrochloride is more effective than a placebo in treating patients with muscle, bone…
- Conditions
- Breast Cancer, Musculoskeletal Complications, Pain
- Trial name
- NCT01598298
- Testing
- duloxetine hydrochloride
- Where
- 714 sites in United States
- Volunteers
- 299 people
- Sponsor
- SWOG Cancer Research Network
Follicular Lymphoma
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma.
- Trial name
- NCT02213263
- Testing
- PF-05280586, MabThera®
- Where
- 423 sites in United States, Austria and 28 more
- Volunteers
- 394 people
- Sponsor
- Pfizer
Methamphetamine Dependence, Substance Abuse
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
Methamphetamine (MA) abuse is the fastest growing drug problem in the United States and is responsible for significant public health complications, including HIV infection.
- Conditions
- Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
- Trial name
- RAVEN (NCT01011829)
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Los Angeles
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
Sleep Apnea Syndromes, Sleep Initiation and Maintenance Disorders
Understanding the Sleep Apnea/Insomnia Interaction
Nearly half of all patients with obstructive sleep apnea have insomnia symptoms, and in some, but not all cases, these insomnia symptoms are caused by the obstructive sleep apnea.
- Trial name
- NCT01824472
- Testing
- CPAP, CBT, CC
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Pennsylvania
Multiple Indications Cancer
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.
- Trial name
- NCT02297139
- Testing
- Dasatinib
- Where
- 6 sites in France, Poland
- Volunteers
- 17 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus Type 2
A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults with type-2 diabetes.
- Trial name
- NCT02097277
- Testing
- BMS-986036
- Where
- 16 sites in United States, Canada
- Volunteers
- 219 people
- Sponsor
- Bristol-Myers Squibb
22q13 Deletion Syndrome, Phelan-McDermid Syndrome
Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)
The purpose of this study is to pilot the use of Insulin-Like Growth Factor-1 (IGF-1) treatment in 22q13 Deletion Syndrome (Phelan-McDermid Syndrome) caused by SHANK3 gene deficiency in order to evaluate safety, tolerability, and…
- Trial name
- NCT01525901
- Testing
- Insulin-Like Growth Factor-1 (IGF-1), Normal saline
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Chronic Low Back Pain
Flurbiprofen Tape for Treatment of Chronic Low Back Pain
The purpose of this trial is to evaluate the analgesic efficacy and safety of flurbiprofen tape for chronic low back pain (lasting greater than 3 months).
- Trial name
- LBP (NCT00759330)
- Testing
- Flurbiprofen Tape (Arm 2), Flurbiprofen Tape (Arm 4)
- Where
- 10 sites in United States
- Volunteers
- 127 people
- Sponsor
- Teikoku Pharma USA, Inc.
Attention-Deficit/Hyperactivity Disorder
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate
This study will evaluate how long it takes for ADHD symptoms to improve in subjects who are judged by the Investigator to have had an inadequate response to methylphenidate therapy.
- Trial name
- NCT01106430
- Testing
- Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride
- Where
- 64 sites in United States, Belgium and 8 more
- Volunteers
- 267 people
- Sponsor
- Shire
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
This phase II trial tests whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine (STEMVAC) works to shrink tumors in patients with stage IV non-small cell lung cancer.
- Trial name
- NCT05242965
- Testing
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
The primary objective of this study was to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT04401800
- Testing
- Lenvatinib, Tislelizumab
- Where
- 9 sites in China
- Volunteers
- 64 people
- Sponsor
- BeiGene
Vomiting, Cisplatin Adverse Reaction
Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy
Gabapentin is an antiepileptic drug. Its antiemetic effect is demonstrated after laparoscopic surgery, but it is not yet known whether gabapentin is effective in preventing chemotherapy induced emesis.
- Trial name
- NCT01052844
- Testing
- Gabapentin
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Faculdade de Medicina do ABC
Stroke
Smartphone and 3D Printing Based Home Rehabilitation System for Chronic Stroke
Interventions promoting optimum motor performance across the lifespan are a priority after a neurological insult such as stroke.
- Trial name
- NCT04363944
- Testing
- mRehab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- State University of New York at Buffalo
Healthy
AZD8848 Single Ascending Dose Study
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of AZD8848 in healthy subjects.
- Trial name
- NCT01560234
- Testing
- AZD8848
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.